Recursion Pharmaceuticals, Inc. (RXRX): Total Assets
$1.47B
As of 2025-12-31
$1.21B
As of 2026-06-30
+28.1%
3-year compound annual growth
+37.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.47B | +1.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $1.45B | +121.6% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $653.70M | -6.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $701.29M | +14.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $610.35M | +104.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $298.58M | n/a | 2022-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗